She is a past Secretary, Therapeutics Subcommittee, Australian Rheumatology Association and Arthritis Australia (ACT). She is a current board member of Optimal Patient outcomes in AustraLian rheumatology (OPAL Pty Ltd). One of her special research interests is Physician optimal use of disease-modifying anti-rheumatic drugs (DMARDs) including biologics in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis combined with Patient shared decision making involving patient medication non adherence factors and patient reported outcomes.